share_log

6-K: Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial

SEC ·  Sep 23 06:28
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more